PARP inhibitor receives FDA breakthrough therapy designation in castration resistant prostate cancer: beyond germline BRCA mutations.

JSON

Helleday T

Ann. Oncol. 27 (5) 755-757 [2016-05-00; online 2016-02-09]

PubMed 26865580

DOI 10.1093/annonc/mdw048

Crossref 10.1093/annonc/mdw048

pii: S0923-7534(19)37429-0